BR0313946A - Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método - Google Patents

Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método

Info

Publication number
BR0313946A
BR0313946A BR0313946-8A BR0313946A BR0313946A BR 0313946 A BR0313946 A BR 0313946A BR 0313946 A BR0313946 A BR 0313946A BR 0313946 A BR0313946 A BR 0313946A
Authority
BR
Brazil
Prior art keywords
compounds
modulated
pharmaceutical compositions
treating
ppara
Prior art date
Application number
BR0313946-8A
Other languages
English (en)
Inventor
Alfred Binggeli
Uwe Grether
Hans Hilpert
Georges Hirth
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0313946A publication Critical patent/BR0313946A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS, PROCESSO PARA A MANUFATURA DESSES COMPOSTOS, COMPOSIçõES FARMACêUTICAS QUE COMPREENDEM OS MESMOS, MéTODO PARA O TRATAMENTO E/OU PREVENçãO DE ENFERMIDADES QUE SãO MODULADAS POR AGONISTAS PPAR<244> E/OU PPAR<sym>, UTILIZAçãO DOS COMPOSTOS E/OU DO MéTODO". A presente invenção refere-se a compostos da fórmula (I) em que R^ 1^ a R^ 10^, X, Y e n são tais como definidos na descrição e reivindicações, e seus sais e ésteres farmaceuticamente aceitáveis. Os compostos são de utilidade para o tratamento de enfermidades, tais como diabetes.
BR0313946-8A 2002-08-30 2003-08-21 Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método BR0313946A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02019146 2002-08-30
PCT/EP2003/009281 WO2004020420A1 (en) 2002-08-30 2003-08-21 Novel 2-arylthiazole compounds as pparalpha and ppargama agonists

Publications (1)

Publication Number Publication Date
BR0313946A true BR0313946A (pt) 2005-07-12

Family

ID=31970267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313946-8A BR0313946A (pt) 2002-08-30 2003-08-21 Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método

Country Status (30)

Country Link
US (1) US6809110B2 (pt)
EP (1) EP1537091B1 (pt)
JP (2) JP4533141B2 (pt)
KR (1) KR100736955B1 (pt)
CN (1) CN100475810C (pt)
AR (1) AR041079A1 (pt)
AT (1) ATE483699T1 (pt)
BR (1) BR0313946A (pt)
CA (1) CA2495942C (pt)
DE (1) DE60334461D1 (pt)
DK (1) DK1537091T3 (pt)
ES (1) ES2350340T3 (pt)
GT (1) GT200300183A (pt)
HK (1) HK1082504A1 (pt)
HR (1) HRP20050158A2 (pt)
IL (1) IL166833A (pt)
MX (1) MXPA05002115A (pt)
MY (1) MY141020A (pt)
NO (1) NO329777B1 (pt)
NZ (1) NZ537897A (pt)
PA (1) PA8581201A1 (pt)
PE (1) PE20040982A1 (pt)
PL (1) PL375779A1 (pt)
PT (1) PT1537091E (pt)
RU (1) RU2296754C2 (pt)
SI (1) SI1537091T1 (pt)
TW (1) TWI338686B (pt)
UY (1) UY27959A1 (pt)
WO (1) WO2004020420A1 (pt)
ZA (1) ZA200501097B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
JP2009084156A (ja) * 2006-01-18 2009-04-23 Nissan Chem Ind Ltd チアゾール置換アセトニトリルの製造方法
WO2008108602A1 (en) * 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
JP2010520873A (ja) * 2007-03-07 2010-06-17 ドン・ア・ファーム・カンパニー・リミテッド ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体、その方法およびそれを含む医薬組成物
DE102007038251A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
CN101928259B (zh) * 2009-06-18 2012-10-03 南京海辰药业有限公司 2-芳基噻唑衍生物及其药物组合物
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
EP3478297A1 (en) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
US20200172530A1 (en) * 2017-03-14 2020-06-04 Dana-Farber Cancer Institute, Inc. Small Molecule Sensitization of BAX Activation for Induction of Cell Death
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH07508747A (ja) 1992-07-03 1995-09-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 医薬用複素環化合物
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
TW476758B (en) 1996-12-10 2002-02-21 Bristol Myers Squibb Co Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1078923T3 (da) 1999-08-02 2006-07-10 Hoffmann La Roche Fremgangsmåde til fremstilling af benzothiophenderivater
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
CN1471517A (zh) * 2000-08-23 2004-01-28 Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途
ES2264482T3 (es) * 2001-05-15 2007-01-01 F. Hoffmann-La Roche Ag Derivados de oxazol sustituidos por acido carboxilico para uso como activadores de ppar-alfa y gamma en el tratamiento de diabetes.
ES2316736T3 (es) * 2002-02-25 2009-04-16 Eli Lilly And Company Moduladores de receptores activados por proliferador de peroxisoma.
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister

Also Published As

Publication number Publication date
ES2350340T3 (es) 2011-01-21
GT200300183A (es) 2004-04-15
EP1537091B1 (en) 2010-10-06
IL166833A (en) 2010-12-30
TWI338686B (en) 2011-03-11
AU2003273801A1 (en) 2004-03-19
AR041079A1 (es) 2005-04-27
HK1082504A1 (en) 2006-06-09
CN1678596A (zh) 2005-10-05
ATE483699T1 (de) 2010-10-15
DK1537091T3 (da) 2010-11-08
PA8581201A1 (es) 2004-09-16
WO2004020420A1 (en) 2004-03-11
CA2495942A1 (en) 2004-03-11
US6809110B2 (en) 2004-10-26
ZA200501097B (en) 2006-11-29
HRP20050158A2 (en) 2006-11-30
MXPA05002115A (es) 2005-05-23
JP2010132671A (ja) 2010-06-17
NO20050620L (no) 2005-03-03
MY141020A (en) 2010-02-25
EP1537091A1 (en) 2005-06-08
SI1537091T1 (sl) 2010-12-31
RU2005109163A (ru) 2006-01-20
DE60334461D1 (de) 2010-11-18
JP2006502151A (ja) 2006-01-19
PE20040982A1 (es) 2004-12-30
JP4533141B2 (ja) 2010-09-01
RU2296754C2 (ru) 2007-04-10
US20040110807A1 (en) 2004-06-10
CN100475810C (zh) 2009-04-08
TW200407133A (en) 2004-05-16
CA2495942C (en) 2010-03-23
NZ537897A (en) 2007-08-31
KR100736955B1 (ko) 2007-07-09
KR20050057083A (ko) 2005-06-16
PL375779A1 (en) 2005-12-12
PT1537091E (pt) 2010-11-11
NO329777B1 (no) 2010-12-13
UY27959A1 (es) 2004-02-27

Similar Documents

Publication Publication Date Title
BR0316091A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0215396A (pt) Compostos, processo para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com &#34;dpp-iv&#34; e utilização dos compostos
BRPI0416283A (pt) compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
BR0307665A (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
BRPI0516667A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos
BR0313946A (pt) Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método
BRPI0517559A (pt) composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0518907A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de h3 e sua utilizaÇço
BRPI0411713A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BRPI0411509A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BR0317926A (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e utilização dos mesmos
BR0317931A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização dos compostos
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
BRPI0607861A2 (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0512237A (pt) cis-imidazolinas
BRPI0516842A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
BR0307576A (pt) Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
BRPI0613570A8 (pt) composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.